|Ultima descărcare din IBN:|
| SM ISO690:2012|
FEGHIU, Veronica; ROBU, Maria; TOMACINSCHII, Victor; BURUIANA, Sanda; POPESCU, Maria; DUDNIC, Cristina. Rezultatele tratamentului limfoamelor Non-Hodgkin agresive cu afectarea primară a ganglionilor limfatici abdominali. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”. 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 217.
|Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020|
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" |
Chişinău, Moldova, 21-23 octombrie 2020
Background. Non-Hodgkin's lymphomas (NHL) are malignant tumors of lymphatic tissue. One of the primary involvements of NHL is abdominal lymph nodes. Their frequency constitutes 7.6 8.2%. Objective of the study. To evaluate aggressive NHL with primary abdominal lymph nodes involvement treatment results. Material and Methods. Treatment outcomes were studied in 37 patients with aggressive NHL with primary abdominal lymph nodes involvement, aged between 25 and 73 years. Polychemotherapy (PChT) cycles were used for treatment: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) - in 24 patients and rituximab + CHOP (R-CHOP) - in 13 patients. Results. Complete remissions were obtained in 48.7% of cases. Complete remissions rate (CRR) was higher (69.2%) when PChT R-CHOP was administered, comparing to patients in whom PChT CHOP (37.5%) was used. Progression-free survival (PFS) over 5 years was higher in patients who recieved PChT R-CHOP (74.2%). PFS in the same terms in cases when PChT CHOP was given was equal to 59.0%. Conclusion. Adding anti-CD20 monoclonal antibodies (rituximab) to the standard PChT CHOP regimen contributed significantly to the increase of CRR and PFS.
Non-Hodgkin lymphoma, treatment,
limfoame non-Hodgkin, Tratament